--- title: "ENvue Medical announces 1-for-12 reverse stock split effective September 1" url: "https://aibio.space/news/envue-medical-announces-1-12-reverse-stock-split-effective-september-1/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-28" section: "Listings" tickers: "OTC:FEED" source: "https://www.sec.gov/Archives/edgar/data/1326706/000149315226040814/ex99-1.htm" summary: "Each 12 shares will combine into one, which would reduce the 11,084,616 common shares outstanding to about 923,718. The release says trading begins on the" --- By the aibio.space news desk. Sources - [ENvue Medical press release (Form 8-K, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1326706/000149315226040814/ex99-1.htm) - [ENvue Medical, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1326706/000149315226016871/) [FEED](https://aibio.space/companies/envue-medical/) 2026-08-28 # ENvue Medical announces 1-for-12 reverse stock split effective September 1 Tickers [FEED](https://aibio.space/companies/envue-medical/) Each 12 shares will combine into one, which would reduce the 11,084,616 common shares outstanding to about 923,718. The release says trading begins on the Nasdaq Capital Market on September 1, 2026, under the FEED symbol. ## Key facts - **Company**: ENvue Medical, Inc. (OTC: FEED) - **News type**: Listings - **Primary source**: [ENvue Medical press release (Form 8-K, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1326706/000149315226040814/ex99-1.htm) *A supreme court building with lit columns. CC0, via rawpixel. The picture shows the field, not the companies named.* ENvue Medical, Inc. (NASDAQ: [FEED](https://aibio.space/companies/envue-medical/)) announced on August 28, 2026 that a 1-for-12 reverse stock split of its common stock is expected to become effective on September 1, 2026. The company said its common stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open that day. The symbol stays FEED, but the shares will trade under a new CUSIP number. ## The split Under the split, each 12 shares of common stock will be combined into one share. The company said that reduces its 11,084,616 common shares outstanding to approximately 923,718 shares. No fractional shares will be issued. Any fractional share resulting from the split will be rounded up to the nearest whole share on a per-stockholder basis. The split does not change the 40,000,000 authorized common shares, the number of authorized preferred shares, or the par value of either class. The company said it will not change any stockholder's percentage ownership or voting power, except for minimal effects from the treatment of fractional shares. Options, convertible securities including preferred stock, restricted stock, restricted stock units and warrants outstanding before the split will be adjusted appropriately. The board of directors approved the split under authority granted by stockholders at a special meeting held on August 14, 2026. VStock Transfer, LLC will act as the exchange agent for the split. ## The company ENvue describes itself as a commercial-stage medical technology company focused on non-invasive solutions for enteral care in clinical and home care settings. It is headquartered in Tyler, Texas, with research and development in Tel Aviv, Israel. The release says the ENvue Navigation Platform is developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel. Its ENvue Navigation Platform is a minimally invasive electromagnetic navigation system intended to help clinicians place feeding tubes into the gastrointestinal tract. The release says the system is FDA 510(k) cleared for adult use and gives real-time bedside visualization of tube movement during placement. Future platform expansion may include pediatric and vascular access applications. The release describes two distinct technology platforms. The second platform covers acoustic-based therapeutic technologies, including PainShield and UroShield, which use low-intensity surface acoustic wave technology. The release says these devices are intended for home or care settings and are designed to treat pain, reduce bacterial colonization and disrupt biofilms. Manufacturing operations are in the United States. ## Financial position The 10-K filed April 15, 2026 reports research and development expense of $1.8 million for 2025, compared with $909,000 for 2024. The net loss was $18.2 million in 2025, against $3.7 million in 2024. Cash from operations was negative $9.4 million in 2025 and negative $2.5 million in 2024. At year-end 2024, cash and cash equivalents were $752,000. A later quarterly report gives cash and cash equivalents of $1.1 million at June 30, 2026, down from $4.2 million at year-end 2025. ## What the split does not fix The release gives no reason for the split, no share price and no mention of a Nasdaq listing notice, so the motive is not stated. A reverse split changes the number of shares, not what the company earns or owns. After the split the company would have approximately 923,718 shares outstanding. The financial position is the harder problem. The net loss for 2025 was $18.2 million, up from $3.7 million, and cash used in operations rose to $9.4 million from $2.5 million. Against that, cash on hand was $1.1 million at June 30, 2026, a gap the release does not address and the company does not say how it will fund. Options, convertible securities, preferred stock and warrants outstanding before the split will be adjusted, so conversion into new shares remains possible. The release does not give a further timetable for the company's plans. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story FEED ENvue Medical, Inc. OTC ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/envue-medical-announces-1-12-reverse-stock-split-effective-september-1/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ENvue Medical announces 1-for-12 reverse stock split effective September 1", 2026-08-28, https://aibio.space/news/envue-medical-announces-1-12-reverse-stock-split-effective-september-1/